Gyre Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 6, 2026, covering the fiscal quarter and nine months ended September 30, 2026, disclosing a net loss attributable to common stockholders of $28.9 million for the nine-month period.

Key Highlights

  • Revenue: The company reported revenues of $86,469 thousand for the nine months ended September 30, 2026, compared with $92,999 thousand for the same period in 2025.
  • Net loss: Net loss attributable to common stockholders was $28,862 thousand for the nine months ended September 30, 2026, versus net income of $1,151 thousand in the prior-year period.
  • Q3 revenue: Revenues for the three months ended September 30, 2026 were $32,934 thousand, up slightly from $32,694 thousand in Q3 2025.
  • Operating loss: Loss from operations for the nine-month period totaled $34,857 thousand, compared with income from operations of $1,796 thousand in the nine months ended September 30, 2025.
  • Total assets: Total assets stood at $201,251 thousand as of September 30, 2026, down from $219,763 thousand at December 31, 2025.
  • Shares outstanding: As of November 1, 2026, there were 115,321,017 shares of common stock outstanding, including 5,869,446 shares issued to a stock plan administrator.
  • Series B preferred stock: 3,552,427 shares of Series B preferred stock were issued and outstanding at September 30, 2026, valued at $21,551 thousand, compared with zero shares at December 31, 2025.

Operating Results and Balance Sheet Shifts at Gyre Therapeutics for the Nine Months Ended September 30, 2026

According to the filing, Gyre Therapeutics, a Delaware-incorporated biopharmaceutical company headquartered in San Diego, California, and listed on NASDAQ:GYRE, generated revenues of $86,469 thousand in the nine months ended September 30, 2026, a decline from $92,999 thousand in the comparable prior-year period. Total operating expenses rose substantially year-over-year, reaching $121,326 thousand for the nine-month period versus $91,203 thousand in 2025. The company disclosed that selling and marketing expenses were $42,918 thousand and research and development expenses totaled $34,265 thousand for the nine months, reflecting meaningful increases from $41,363 thousand and $24,239 thousand, respectively, in the prior-year period.

The filing also disclosed $6,936 thousand in transaction costs for the nine months ended September 30, 2026, an item that did not appear in the same period of 2025. General and administrative expenses increased to $26,964 thousand from $21,928 thousand in the prior-year nine-month period. These cost increases contributed to a loss from operations of $34,857 thousand for the nine months, contrasting with operating income of $1,796 thousand in 2025. For the three months ended September 30, 2026, the company reported a loss from operations of $1,520 thousand.

On the balance sheet, cash and cash equivalents were $41,643 thousand at September 30, 2026, compared with $49,192 thousand at December 31, 2025. The accumulated deficit widened to $142,015 thousand from $112,603 thousand over the same interval, according to the filing. Total equity increased to $144,517 thousand from $59,545 thousand, partly reflecting changes in noncontrolling interest, which moved from $(2,952) thousand to $36,563 thousand. The registrant is classified as an accelerated filer and a smaller reporting company.

What Was Disclosed

Gyre Therapeutics disclosed its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026, including revenues, operating losses, balance sheet positions, share counts, and changes in equity structure including the issuance of Series B preferred stock.